Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROVIDENCE: Pyronaridine-artesunate (Artecom) for COVID-19
NCT04701606Phase 3Unknown
- Sponsor
- Shinpoong Pharma
- Start
- Mar 2021
- Primary completion
- Apr 2022
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of dihydroartemisinin + piperaquine in coronavirus disease 2019 (COVID-19), sponsored by Shinpoong Pharma. Status: unknown.
02
Drugs
dihydroartemisinin + piperaquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04701606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04701606.